gp100 plasmid DNA vaccine

The **gp100 plasmid DNA vaccine** is an investigational DNA-based vaccine designed to induce an immune response against the gp100 antigen, a melanocyte differentiation antigen widely expressed on melanoma cells. The vaccine consists of a plasmid encoding either mouse or human gp100, which is delivered via intramuscular injection or particle-mediated epidermal delivery. The DNA is incorporated into a vector (commonly pING) under a cytomegalovirus promoter for eukaryotic expression. Once taken up by host cells, the gp100 antigen is expressed intracellularly, processed, and presented on MHC molecules, leading to the activation of CD8+ cytotoxic T cells targeting gp100-expressing tumor cells. The vaccine is being developed as an adjuvant or therapeutic immunotherapy in melanoma, particularly in high-risk or advanced (stage IIB-IV) settings. It is under investigation in combination with other immunotherapies (e.g., checkpoint inhibitors). Clinical production has been performed to cGMP standards and evaluated in phase I clinical trials for safety and immunogenicity. The vaccine has demonstrated a favorable safety profile with injection site reactions as the most common adverse event, and immune responses have been observed in some recipients[1][2][7].

Other names

xenogeneic gp100 DNA vaccinegp100 pING DNA vaccinegp-100 pING DNA vaccinegp 100 pING DNA vaccine